6 August 2026
1QFY27 Results Update | Sector: Midcap

Godrej Agrovet

Estimate change	↔
TP change	↔
Rating change	↔

Bloomberg	GOAGRO IN
Equity Shares (m)	192
M.Cap.(INRb)/(USDb)	104.6 / 1.1
52-Week Range (INR)	851 / 506
1, 6, 12 Rel. Per (%)	-5/2/-35
12M Avg Val (INR M)	147

Financials & Valuations (INR b)

Y/E MARCH	2026	2027E	2028E
Sales	102.3	116.2	125.1
EBITDA	8.6	10.4	11.7
Adj. PAT	5.0	5.8	6.9
EBITDA Margin (%)	8.4	9.0	9.4
Cons. Adj. EPS (INR)	25.8	30.2	36.0
EPS Gr. (%)	15.3	17.2	19.0
BV/Sh. (INR)	106	126	151
Ratios			
Net D:E	0.6	0.6	0.4
RoE (%)	22.5	26.1	26.0
RoCE (%)	14.3	16.5	17.6
Payout (%)	42.7	34.7	29.2
Valuations			
P/E (x)	21.1	18.0	15.1
EV/EBITDA (x)	13.7	11.4	9.9
Div. Yield (%)	1.9	1.9	1.9
FCF Yield (%)	10	1	5

Shareholding pattern (%)

	Jun-26	Mar-26	Jun-25
Promoter	67.7	67.7	67.5
DII	7.7	8.3	8.1
FII	4.1	3.8	4.2
Others	20.5	20.1	20.2

Note: FII includes depository receipts

CMP: INR545 TP: INR675 (+24%) Buy

Near-term weakness with recovery underway

Operating performance misses due to weaker-than-expected gross margins

- Godrej Agrovet (GOAGRO) reported subdued operating performance in 1QFY27, with EBIT declining ~13% YoY due to a significant 35% YoY decline in the Crop Care business caused by delayed monsoons and slower kharif sowing. In contrast, Animal Feed and Vegetable Oil businesses delivered strong performance, with EBIT growth of 30%/15% YoY, respectively.
- The company's strategic move of product diversification across key crops in the Crop Care business, the evolution of the Animal Feed business into animal nutrition, downstream expansion in Palm Oil business, and enhancing share of value-added products in Godrej Foods are expected to drive earnings going forward. Moreover, the ramp-up of the Astec business is likely to further accelerate the company's growth trajectory.
- We have broadly maintained our earnings estimates for FY27 and FY28 and **reiterate our BUY rating on the stock with an SOTP-based TP of INR675.**

Operational performance impacted by input cost pressures

- Consolidated revenue stood at INR28.5b, up 9% YoY (est. in line). EBITDA margin contracted 190bp YoY to 8.4% (est. 10.1%), led by gross margin contraction of 275bp YoY to 24.9%. EBITDA stood at INR2.4b, down 11% YoY (est. INR2.8b). Adjusted PAT declined ~16% YoY to INR1.3b (est. of INR1.6b).
- **AF:** Revenue grew 12.6% YoY to INR13b, with volumes growing ~7% YoY and realizations improving 5% YoY. EBIT margins expanded 85bp to 6.4%, driven by benefits from strategic commodity sourcing and higher operating leverage.
- **Palm Oil:** Revenue increased 24% YoY to INR6.1b, driven by a sharp expansion in CPO and PKO realizations (18% and 19.5% YoY). EBIT margin contracted 131bp YoY to 16.1%. EBIT grew ~14.7% YoY to INR996m.
- **CP**: Consolidated CP revenue declined 13% YoY to ~INR3.4b, with standalone CP revenue declining 17.4% YoY and Astec sales growing 5% YoY. Astec's revenue increase was driven by robust growth in the enterprise category (41%YoY), while the CDMO business declined 17% YoY. Consolidated CP EBIT declined 35% YoY to INR756m, with standalone CP EBIT declining 38% YoY to INR860m. Astec achieved breakeven at the EBITDA level.
- The **Dairy** business recorded revenue growth of 11.5% YoY to ~INR4.6b, while it registered EBIT loss of INR19m, driven by elevated procurement costs and industry-wide constraints in milk availability. The **Poultry and Processed Food** business reported revenue of INR1.8b, flat YoY, while EBIT was INR9m vs INR45m in 1QFY26, driven by higher input costs and inflationary pressure from geopolitical disruptions.

Research Analyst: Sumant Kumar (Sumant.Kumar@MotilalOswal.com) | **Udit Gajiwala** (Udit.Gajiwala@MotilalOswal.com)
Research Analyst: Nirvik Saini (Nirvik.Saini@MotilalOswal.com) | **Yash Darak** (Yash.darak@MotilalOswal.com)

Highlights from the management commentary

- **Crop protection:** The company aims to recoup the lost business in the coming quarters and remains positive on achieving 26-27% EBIT margin in FY27. GOAGRO's product diversification has gained momentum, with Ashitaka and Takai scaling up and contributing ~18-20% to 1QFY27 sales, partially offsetting the weak demand environment. Further, in May'26, GOAGRO entered the soyabean herbicides segment through the Ghassnash product, with further ramp-up planned in 2QFY27.
- **Palm oil:** Margins were temporarily impacted by formula-based pricing, with management expecting recovery in the coming quarters amid a constructive outlook for the segment. Over the medium term, growth is expected to be driven by plantation expansion, the maturation of existing plantations, and downstream integration. At scale, the downstream expansion is likely to enhance overall margins by ~200bp.
- **Poultry business**: The company is strategically shifting its portfolio toward the higher-growth branded consumer business, with Yummiez volumes constituting ~28% in 1QFY27 and management targeting a ~65-70% contribution mix over the coming years. Investments in new products (frozen chicken, momos) are expected to support growth, while the live bird business will gradually transition into backend supply.

Valuation and view

- GOAGRO's outlook remains positive, supported by its strategic portfolio realignment initiatives, including: i) diversification of its crop protection portfolio, ii) targeted geographic expansion in animal nutrition, iii) investments across the palm oil value chain, and iv) the transition of the animal feed business toward an 'animal nutrition' model.
- Further, improvement in volumes, realizations, and capacity utilization across both Enterprise and CDMO businesses at Astec positions the company for sustained recovery and profitable growth in the coming years.
- We have built in Revenue/EBITDA/Adj. PAT CAGR of 11%/16%/18% over FY26-FY28E. We reiterate our **BUY rating** on the stock with an **SOTP-based TP of INR675**.

Consolidated - Quarterly Earning Model (INR m)

Y/E March	FY26				FY27E				FY26	FY27E	FY27E	Var
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE			1QE	(%)
Gross Sales	**26,143**	**25,674**	**27,183**	**23,327**	**28,552**	**29,159**	**31,607**	**26,864**	**1,02,327**	**1,16,182**	**28,572**	**0**
YoY Change (%)	11.2	4.8	11.0	9.3	9.2	13.6	16.3	15.2	9.1	13.5	9.3	
Total Expenditure	23,446	23,540	24,768	21,937	26,150	26,268	28,480	24,860	93,691	1,05,758	25,681	
EBITDA	**2,697**	**2,134**	**2,416**	**1,389**	**2,402**	**2,891**	**3,127**	**2,004**	**8,636**	**10,424**	**2,891**	**-17**
Margins (%)	10.3	8.3	8.9	6.0	8.4	9.9	9.9	7.5	8.4	9.0	10.1	
Depreciation	579	571	559	580	567	650	730	788	2,289	2,735	635	
Interest	355	396	347	286	298	330	380	411	1,383	1,419	390	
Other Income	119	78	183	678	148	120	150	93	1,058	511	80	
PBT before EO expense	**1,882**	**1,246**	**1,693**	**1,202**	**1,685**	**2,031**	**2,167**	**898**	**6,023**	**6,781**	**1,946**	
Extra-Ord expense	0	0	304	0	0	0	0	0	304	0	0	
PBT	**1,882**	**1,246**	**1,389**	**1,202**	**1,685**	**2,031**	**2,167**	**898**	**5,718**	**6,781**	**1,946**	
Tax	517	507	367	277	528	539	433	206	1,668	1,707	490	
Rate (%)	27.5	40.7	26.5	23.1	31.3	26.5	20.0	23.0	29.2	25.2	25.2	
MI & P/L of Asso. Cos.	-240	-187	-127	-124	-188	-160	-165	-199	-678	-712	-170	
Reported PAT	**1,605**	**926**	**1,148**	**1,049**	**1,345**	**1,653**	**1,899**	**890**	**4,728**	**5,786**	**1,626**	
Adj PAT	**1,605**	**926**	**1,377**	**1,049**	**1,345**	**1,653**	**1,899**	**890**	**4,956**	**5,786**	**1,626**	**-17**
YoY Change (%)	18.8	-17.6	23.5	48.1	-16.2	78.5	37.9	-15.1	15.3	16.8	0.0	
Margins (%)	6.1	3.6	5.1	4.5	4.7	5.7	6.0	3.3	4.8	5.0	5.7	

E: MOFSL Estimates

Key Performance Indicators

Y/E March	FY26				FY27	FY26
	1Q	2Q	3Q	4Q	1Q	
Segment Revenue Gr. (%)						
Animal Feed (AF)	0.1	1.0	1.9	10.8	12.6	3.4
Palm Oil	91.7	45.3	28.5	-5.1	24.1	39.4
Crop Protection	10.4	-28.3	34.4	15.6	-13.3	5.6
Dairy	-2.7	-2.4	2.7	3.9	11.5	0.2
Segment EBIT Margin (%)						
Animal Feed	5.6	5.8	6.2	10.4	6.4	7.0
Palm Oil	17.4	21.6	23.1	7.0	16.1	19.3
Crop Protection	28.9	7.7	7.7	8.5	21.6	15.1
Dairy	1.0	2.3	1.2	0.4	-0.4	1.2
AF Volumes (000'MT)	**375**	**400**	**445**	**426**	**402**	**1,361**
AF Realization (INR/kg)	**30.8**	**30.4**	**29.2**	**29.8**	**32.4**	**30.0**
Cost Break-up						
RM Cost (% of sales)	72.4	73.4	74.0	76.6	75.1	**74.0**
Staff Cost (% of sales)	6.1	6.4	6.1	6.2	5.7	**6.2**
Other Cost (% of sales)	11.1	11.9	11.0	11.2	10.8	**11.3**
Gross Margins (%)	27.6	26.6	26.0	23.4	24.9	**26.0**
EBITDA Margins (%)	10.3	8.3	8.9	6.0	8.4	**8.4**
EBIT Margins (%)	8.1	6.1	6.8	3.5	6.4	**6.2**

Key exhibits

Exhibit 1: Consolidated revenue trend



Source: Company, MOFSL

Exhibit 2: Consolidated EBITDA trend



Source: Company, MOFSL

Exhibit 3: Consolidated adjusted PAT trend



Source: Company, MOFSL

Exhibit 4: Animal Feed business

Particulars	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26	4QFY26	1QFY27
Volume (MT)	3,45,948	3,61,597	3,97,498	3,70,104	3,75,139	4,00,094	4,45,060	4,26,252	4,02,257
Growth (%)	-7.6	-2.9	1.8	2.2	8.4	10.6	12.0	15.2	7.2
Revenue (INR m)	11,554	12,054	12,742	11,463	11,562	12,171	12,984	12,699	13,021
Growth (%)	-10.1	-3.0	-1.3	-3.6	0.1	1.0	1.9	10.8	12.6
EBIT (INR m)	781.2	706.3	769.2	654.4	645.2	702.9	807.1	1316.6	836.8
Margin (%)	6.8	5.9	6.0	5.7	5.6	5.8	6.2	10.4	6.4
Growth (%)	44.7	23.8	47.2	-3.6	-17.4	-0.5	4.9	101.2	29.7

Exhibit 5: Consolidated Crop Protection business

Particulars	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26	4QFY26	1QFY27
Revenue (INR m)	3,645	2,967	1,934	2,708	4,026	2,128	2,599	3,131	3,490
Growth (%)	-4.6	-21.7	-13.1	6.4	10.4	-28.3	34.4	15.6	-13.3
EBIT (INR m)	868	551	119	457	1,165	163	200	265	756
Margin (%)	23.8	18.6	6.2	16.9	28.9	7.7	7.7	8.5	21.6
Growth (%)	8.5	-15.1	-52.0	-2.4	34.2	-70.4	67.5	-42.0	-35.1

Exhibit 6: Standalone Crop Protection business

Particulars	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26	4QFY26	1QFY27
Revenue (INR m)	3,140	1,980	990	1,530	3,280	1,390	1,360	1,680	2,710
Growth (%)	18.9	-23.8	-42.4	28.6	4.5	-29.8	37.4	9.8	-17.4
EBIT (INR m)	1,420	850	270	540	1,380	320	260	270	860
Margin (%)	45.2	42.9	27.3	35.3	42.1	23.0	19.1	16.1	31.7
Growth (%)	67.0	10.3	-48.1	31.7	-2.8	-62.4	-3.7	-50.0	-37.7

Exhibit 7: Astec Lifesciences business

Particulars	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26	4QFY26	1QFY27
Revenue (INR m)	505	987	944	1,178	746	738	1,239	1,451	780
Growth (%)	-57.2	-17.0	87.1	-13.0	47.7	-25.3	31.2	23.2	4.6
EBITDA (INR m)	-453	-177	-38	63	-110	-56	48	118	0
Margin (%)	-89.7	-17.9	-4.0	5.3	-14.8	-7.6	3.9	8.1	0.0
Growth (%)	-1006.0	643.8	-77.6	-58.0	-75.7	-68.4	-226.3	87.3	-100.0

Exhibit 8: Palm Oil business

Particulars	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26	4QFY26	1QFY27
Revenue (INR m)	1,875	2,604	4,407	4,877	2,439	4,991	6,403	6,269	2,314	6,192
Growth (%)	28.3	12.4	-1.5	37.6	30.1	91.7	45.3	28.5	-5.1	24.1
EBIT (INR m)	92	241	736	1,154	184	868	1,385	1,446	162	996
Margin (%)	4.9	9.2	16.7	23.7	7.5	17.4	21.6	23.1	7.0	16.1
Growth (%)	-49.9	-14.1	7.1	71.7	100.0	260.5	88.1	25.3	-11.8	14.7

Exhibit 9: Dairy business

Particulars	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26	4QFY26	1QFY27
Revenue (INR m)	4,286	4,027	3,698	3,842	4,168	3,932	3,798	3,992	4,646
Growth (%)	1.0	3.2	1.0	-2.0	-2.7	-2.4	2.7	3.9	11.5
EBITDA (INR m)	47	47	47	47	47	47	47	47	47
Margin (%)	1.1	1.2	1.3	1.2	1.1	1.2	1.2	1.2	1.0
Growth (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT (INR m)	185.3	84.3	92.6	66.1	43.1	90.8	46.9	16	-19
Margin (%)	4.3	2.1	2.5	1.7	1.0	2.3	1.2	0.4	-0.4

Exhibit 10: Poultry and Processed Foods business

Particulars	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26	4QFY26	1QFY27
Revenue (INR m)	2,342	1,973	2,155	1,788	1,869	1,826	2,155	1,832	1,882
Growth (%)	-24.5	-16.7	-3.3	-17.4	-20.2	-7.4	0.0	2.5	0.7
EBIT (INR m)	193	5	65	41	45	23	127	126	9
Margin (%)	8.2	0.3	3.0	2.3	2.4	1.3	5.9	6.9	0.5
Growth (%)	-28.4	-96.6	-188.9	-65.9	-76.8	356.9	94.5	208.6	-80.5

Source: Company, MOFSL

CONFERENCE CALL

Highlights from the management commentary

Animal nutrition (AF)

- Revenue grew ~13% YoY, led by 7% volume growth and improved realizations.
- Cattle feed volumes grew ~15% YoY and fish business grew ~20% YoY. Fish business contributes ~7%. Cattle mix stands at ~55-56%
- Margins expanded 80bps YoY to 6.4%, reflecting benefits of commodity sourcing, operating leverage, and cost discipline.
- 60-70% of input cost increase were passed on to customers.
- The Bangladesh business is recovery well, with double-digit volumes growth during 1QFY27.

Crop protection

- Demand was muted during the quarter amid delayed monsoon progress and slower kharif sowings following one of the driest June.
- Revenue declined due to lower volumes of in-house cotton herbicide, resulting in lower margins.
- The scale-up of Ashitaka (Maize Herbicide) and Takai (Paddy insecticide) helped partially mitigate the impact of adverse market conditions during the quarter, and these products are gaining strong traction.
- Ashitaka volumes scaled 3x YoY, reaching 30kL during the quarter. A new commercialization team has been set up to launch such patented solutions. In 3QFY27, there will be another opportunity in the Southern region for this product.
- Takai's label claims are approved for five additional crops. 13 kL sales in 1Q and scale up are in process. This crop has 5-6 months of saleable time per annum.
- Both the above new products constituted ~18-20% of total sales during 1Q.
- The company entered soyabean herbicide through 'Ghassnash' launched in May'26. 26kL sales were recorded in 1Q, with further ramp-up planned in 2Q.
- Erratic rainfall patterns continue to persist, but Jul'26 is turning out to be better YoY (soft base). By Sep'26-end, the company expects a better outlook for this segment.
- Chilli and grape businesses were affected in 3QFY26, and the company is not expecting such adverse weather conditions during 3QFY27.
- The margin profile of new products is lower.
- Management has guided for ~26-27% of EBIT margin.

Astec LifeSciences

- Revenue declined primarily due to a change in the product mix.
- Operational recovery has helped to narrow down losses.
- The business continued to achieve breakeven (v/s INR110m EBITDA loss YoY).
- More than 20% revenue growth guidance has been provided by the company. CDMO business orders are being shifted from 1HFY27 to 2HFY27.
- Enterprise margins were increased due to low-cost inventory; CDMO margins are intact.

Dairy

- The segment reported ~11% YoY growth, primarily driven by strong volume growth in value-added products. The VAP mix stood at 49% during the quarter (vs 42% YoY), reflecting the company's premiumization strategy.
- Volumes grew ~8% during the quarter.

- Margins were impacted by elevated milk procurement prices amid industry-wide constraints in milk availability, together with war-led inflation in certain other inputs. Packaging costs were shot up due to ME conflict. Packaging crisis might recover by Aug, and the company is undertaking initiatives to minimalize impact in 2HFY27.
- The business is undergoing an 18-month exercise of route-to-market transformation. The company targets to double down on VAP and increase premiumization.

Palm Oil

- Revenue grew ~29% YoY, led by improved realizations, higher sales volumes, and oil extraction efficiency (18.4% to 18.8%)
- Crude palm oil/Palm kernel oil realizations were up ~18%/20% YoY.
- Fresh-fruit bunch (FFB) volumes remained broadly flat despite a high-comparable base in 1QFY26, which had benefited from the early onset of the monsoon.
- Margins were impacted by formula-based pricing, and the company expects that such margin impact will not occur in the coming quarters.
- The company has guided for high-single to early double-digit growth over the next 4-5 years, driven by plantation expansion (17k hectares in FY27), geographic expansion, maturing plantations, and better operating efficiencies.
- Further, the company is also investing across the value chain with seed garden and refinery over the next 14-18 months. Downstream business is anticipated to add ~200bp to overall margin profile, with IRR of ~16-18%.
- The outlook for palm oil is positive, and recovery in margins is expected over the coming quarters.

Godrej food limited (Poultry)

- Branded volume grew ~6% YoY in 1QFY27, offsetting the impact of deliberate reduction in live bird volumes.
- Yummiez grew ~22% YoY.
- Margins moderated due to higher input costs and inflationary pressure from geopolitical disruptions. While the company implemented calibrated pricing actions, the increase in costs could only be partially mitigated.
- Live birds will trail down in the coming 3-4 years and will eventually serve as backend supply for other segments. The business is expected to contribute marginal revenue of ~INR200-300m.
- The company is looking to scale up consumer business (Yummiez) and has grown ~28% in terms of volumes during the quarter. It aims to generate ~65-70% sales mix from this segment in the coming years, with investments already being undertaken to strengthen this business.
- Wet momos products will be rolled out in some months. The company is betting heavily on frozen chicken and has advantage in the supply chain.

Bangladesh JV

- The business made a strong comeback, delivering robust topline growth in the quarter, driven predominantly by broad-based double-digit volume expansion across categories.

Outlook

- Management is targeting double-digit growth but remains cautious.
- It has maintained a capex guidance of INR3-3.5b.
- EBITDA/t guidance is maintained at INR2,100-2,250 for Animal Feeds.
- The company is looking to synergize diary and animal feed segments.

Valuation and view

- GOAGRO's outlook remains positive, supported by its strategic portfolio realignment initiatives, including: i) diversification of the crop protection portfolio, ii) targeted geographic expansion in animal nutrition, iii) investment across the palm oil value chain, and iv) the transition of the animal feed business toward an 'animal nutrition' model.
- Further, improvement in volumes, realizations, and capacity utilization across both Enterprise and CDMO businesses at Astec positions the company for sustained recovery and profitable growth in the coming years.
- We have built in Revenue/EBITDA/Adj. PAT CAGR of 11%/16%/18% over FY26-FY28E. We reiterate our **BUY rating** on the stock with an **SOTP-based TP of INR675**.

Exhibit 11: Valuations

Particulars	FY28 EBITDA (INRm)	EV/ EBITDA (x)	EV (INRm)	Net Debt (INRm)	Equity Value (INRm)	GOAGRO's share (%)	Value (INRm)	Value/ share (INR)
Standalone:								
Crop Protection	2,916	10	28,289		28,289	100%	28,289	147
Palm Oil	5,183	10	51,001		51,001	100%	51,001	266
Animal Feed	4,533	10	45,331		45,331	100%	45,331	236
Unallocated expenses	-2,759	10	-27,591		-27,591	100%	-27,591	-144
Total	**9,873**	**10**	**97,030**	**10,782**	**86,247**	**100%**	**86,247**	**449**
Subsidiaries:								
Astec (mcap with 20% holdco disc)					11,000	65%	7,124	37
Creamline Dairy	926	11	10,185	-496	10,681	100%	10,681	56
Godrej Tyson Foods Limited & Others	996	11	10,961		10,961	100%	10,961	57
JV/ Associate:								
ACI Godrej Agrovet Private Limited	2,649	11	29,144		29,144	50%	14,572	76
Total	**14,445**	**10**	**1,47,319**		**1,48,033**			**675**

Source: MOFSL

Exhibit 12: Revisions to our estimates

Earnings Change	Old		New		Change	
(INR m)	FY27E	FY28E	FY27E	FY28E	FY27E	FY28E
Revenue	1,16,315	1,25,208	1,16,182	1,25,053	0%	0%
EBITDA	10,809	12,074	10,424	11,700	-4%	-3%
Adj. PAT	6,074	7,126	5,806	6,911	-4%	-3%

Source: MOFSL

Financials and valuations

Consolidated - Income Statement (INR m)

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Total Income from Operations	**62,667**	**83,061**	**93,737**	**95,606**	**93,828**	**1,02,327**	**1,16,182**	**1,25,053**
Change (%)	-8.2	32.5	12.9	2.0	-1.9	9.1	13.5	7.6
Raw Materials	46,078	63,048	73,891	72,437	69,462	75,756	86,447	91,289
Employees Cost	3,764	4,393	4,534	5,391	5,347	6,352	7,087	7,628
Other Expenses	7,187	8,966	10,084	10,763	10,857	11,584	12,224	14,436
Total Expenditure	**57,029**	**76,407**	**88,509**	**88,591**	**85,666**	**93,691**	**1,05,758**	**1,13,354**
% of Sales	91.0	92.0	94.4	92.7	91.3	91.6	91.0	90.6
EBITDA	**5,638**	**6,654**	**5,228**	**7,015**	**8,162**	**8,635**	**10,424**	**11,700**
Margin (%)	9.0	8.0	5.6	7.3	8.7	8.4	9.0	9.4
Depreciation	1,540	1,733	1,855	2,143	2,261	2,289	2,735	2,936
EBIT	**4,098**	**4,921**	**3,373**	**4,872**	**5,901**	**6,347**	**7,689**	**8,764**
Int. and Finance Charges	465	631	991	1,079	1,334	1,383	1,419	1,164
Other Income	396	797	367	413	435	1,058	511	550
PBT bef. EO Exp.	**4,029**	**5,086**	**2,749**	**4,206**	**5,002**	**6,023**	**6,781**	**8,149**
EO Items	0	-173	708	0	0	304	0	0
PBT after EO Exp.	**4,029**	**4,914**	**3,457**	**4,206**	**5,002**	**5,718**	**6,781**	**8,149**
Total Tax	1,055	1,224	823	1,133	1,504	1,669	1,707	2,051
Tax Rate (%)	26.20	24.91	23.81	26.93	30.07	29.18	25.2	25.2
Profit from Associate & MI	-164	-337	-385	-523	-799	-678	-732	-813
Reported PAT	**3,137**	**4,026**	**3,019**	**3,596**	**4,297**	**4,727**	**5,806**	**6,911**
Adjusted PAT	**3,137**	**4,154**	**2,495**	**3,596**	**4,297**	**4,956**	**5,806**	**6,911**
Change (%)	25.0	32.4	-39.9	44.1	19.5	15.3	17.2	19.0
Margin (%)	5.0	5.0	2.7	3.8	4.6	4.8	5.0	5.5

Consolidated - Balance Sheet (INR m)

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Equity Share Capital	1,921	1,921	1,922	1,922	1,922	1,923	1,923	1,923
Total Reserves	18,590	20,763	21,454	23,244	21,886	18,398	22,187	27,082
Net Worth	**20,511**	**22,684**	**23,375**	**25,167**	**23,808**	**20,321**	**24,111**	**29,005**
Minority Interest	4,103	4,203	4,061	4,045	2,216	1,316	1,026	722
Total Loans	9,428	15,660	13,215	13,085	13,672	15,437	14,437	11,437
Deferred Tax Liabilities	1,713	1,559	1,798	1,679	1,433	1,482	1,482	1,482
Capital Employed	**35,755**	**44,105**	**42,449**	**43,975**	**41,130**	**38,556**	**41,056**	**42,646**
Gross Block	26,551	29,372	30,520	34,717	39,206	40,421	43,723	46,609
Less: Accum. Deprn.	6,217	7,950	9,805	11,948	14,209	16,497	19,232	22,168
Net Fixed Assets	**20,334**	**21,422**	**20,715**	**22,770**	**24,998**	**23,924**	**24,492**	**24,441**
Goodwill on Consolidation	2,649	2,649	2,649	2,649	2,649	2,649	2,649	2,649
Capital WIP	1,414	902	2,044	1,915	399	1,785	2,232	1,546
Total Investments	**1,237**	**1,597**	**1,584**	**1,766**	**1,386**	**1,217**	**1,217**	**1,217**
Curr. Assets, Loans&Adv.	**22,355**	**29,271**	**27,867**	**27,933**	**25,727**	**32,128**	**31,406**	**33,719**
Inventory	10,419	14,288	13,441	13,830	12,587	13,582	15,646	16,770
Account Receivables	8,226	9,514	5,740	5,189	5,721	6,729	6,366	6,852
Cash and Bank Balance	509	347	295	529	393	3,021	680	717
Loans and Advances	3,200	5,123	8,390	8,385	7,026	8,796	8,714	9,379
Curr. Liability & Prov.	**12,235**	**11,735**	**12,411**	**13,058**	**14,029**	**23,146**	**20,939**	**20,926**
Account Payables	7,326	6,948	7,043	6,278	8,855	16,508	13,039	12,422
Other Current Liabilities	4,206	3,384	4,459	6,020	4,754	5,892	6,971	7,503
Provisions	703	1,403	909	760	421	746	929	1,000
Net Current Assets	**10,120**	**17,536**	**15,456**	**14,875**	**11,698**	**8,982**	**10,467**	**12,793**
Appl. of Funds	**35,755**	**44,105**	**42,449**	**43,975**	**41,130**	**38,556**	**41,056**	**42,646**

Financials and valuations

Ratios

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Basic (INR)								
EPS	**16.3**	**21.6**	**13.0**	**18.7**	**22.4**	**25.8**	**30.2**	**36.0**
Cash EPS	24.4	30.7	22.7	29.9	34.2	37.7	44.5	51.3
BV/Share	106.8	118.1	121.7	131.1	124.0	105.8	125.6	151.0
DPS	8.0	9.5	9.5	10.0	10.5	10.5	10.5	10.5
Payout (%)	49.0	45.3	60.4	53.5	46.9	42.7	34.7	29.2
Valuation (x)								
P/E	33.3	25.1	41.9	29.1	24.3	21.1	18.0	15.1
Cash P/E	22.3	17.7	24.0	18.2	15.9	14.4	12.2	10.6
P/BV	5.1	4.6	4.5	4.2	4.4	5.1	4.3	3.6
EV/Sales	1.9	1.5	1.3	1.3	1.3	1.2	1.0	0.9
EV/EBITDA	20.8	18.6	23.2	17.3	14.7	13.7	11.4	9.9
Dividend Yield (%)	1.5	1.7	1.7	1.8	1.9	1.9	1.9	1.9
FCF per share	-13.1	-20.2	33.6	14.1	39.5	54.5	4.4	25.3
Return Ratios (%)								
RoE	16.1	19.2	10.8	14.8	17.5	22.5	26.1	26.0
RoCE	12.2	12.6	7.6	10.3	11.7	14.3	16.5	17.6
RoIC	10.2	10.0	6.4	9.1	10.5	12.6	16.6	17.2
Working Capital Ratios								
Fixed Asset Turnover (x)	2.4	2.8	3.1	2.8	2.4	2.5	2.7	2.7
Asset Turnover (x)	1.8	1.9	2.2	2.2	2.3	2.7	2.8	2.9
Inventory (Days)	61	63	52	53	49	48	49	49
Debtor (Days)	48	42	22	20	22	24	20	20
Creditor (Days)	43	31	27	24	34	59	41	36
Leverage Ratio (x)								
Current Ratio	1.8	2.5	2.2	2.1	1.8	1.4	1.5	1.6
Interest Cover Ratio	8.8	7.8	3.4	4.5	4.4	4.6	5.4	7.5
Net Debt/Equity	0.4	0.7	0.6	0.5	0.6	0.6	0.6	0.4

Consolidated - Cash Flow Statement (INR m)

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
OP/(Loss) before Tax	4,531	5,416	2,749	4,206	5,538	6,120	6,781	8,149
Depreciation	1,540	1,733	1,855	2,143	2,261	2,289	2,735	2,936
Interest & Finance Charges	465	631	624	666	1,334	1,383	908	615
Direct Taxes Paid	-1,123	-1,533	-823	-1,237	-1,465	-1,600	-1,707	-2,051
(Inc)/Dec in WC	-5,413	-7,085	4,335	812	2,569	5,574	-4,115	-2,593
CF from Operations	**0**	**-838**	**8,740**	**6,590**	**10,236**	**13,766**	**4,602**	**7,056**
Others	-104	-362	0	190	-542	-954	0	0
CF from Operating incl EO	**-104**	**-1,201**	**8,740**	**6,780**	**9,693**	**12,812**	**4,602**	**7,056**
(Inc)/Dec in FA	-2,406	-2,680	-2,290	-4,068	-2,116	-2,340	-3,750	-2,200
Free Cash Flow	**-2,510**	**-3,880**	**6,449**	**2,712**	**7,577**	**10,471**	**852**	**4,856**
(Pur)/Sale of Investments	-9	-166	12	-182	232	29	0	0
Others	627	765	-564	976	1,069	808	953	1,058
CF from Investments	**-1,787**	**-2,081**	**-2,842**	**-3,273**	**-815**	**-1,504**	**-2,797**	**-1,142**
Issue of Shares	0	0	1	1	1	0	0	0
Inc/(Dec) in Debt	3,579	5,778	-2,445	-130	-274	1,857	-1,000	-3,000
Interest Paid	-430	-602	-991	-1,079	-1,219	-1,288	-1,419	-1,164
Dividend Paid	-1,122	-1,591	-1,824	-1,922	-1,923	-2,116	-2,016	-2,016
Others	-136	-478	-689	-145	-5,598	-7,135	290	304
CF from Fin. Activity	**1,891**	**3,108**	**-5,949**	**-3,275**	**-9,013**	**-8,681**	**-4,146**	**-5,876**
Inc/Dec of Cash	**-1**	**-173**	**-51**	**231**	**-135**	**2,627**	**-2,341**	**38**
Opening Balance	510	509	347	296	527	392	3,019	678
Closing Balance	**509**	**347**	**296**	**527**	**392**	**3,019**	**680**	**717**

Explanation of Investment Rating	
Investment Rating	**Expected return (over 12-month)**
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore.This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL .

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani
Email: nainesh.rajani@motilaloswal.com
Contact: (+65) 8328 0276

Specific Disclosures

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).
   MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
   Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
   MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report:No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
   MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
   MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).
6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN .: 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.